ArticleBMC nephrology2026
The appropriateness of finerenone initiation, dosing, and outcomes in diabetic kidney disease: data from real world practice.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFinerenone has been shown to improve renal outcomes in patients with diabetic kidney disease. Appropriate use according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline criteria are essential to maximize its clinical benefit. However, the initiation and monitoring requirements are complex, making full adherence challenging in real-world practice, especially in resource-limited settings.
methodsThis retrospective study was conducted at Somdech Phra Pinklao Hospital, Bangkok, Thailand, and included all adult patients who received finerenone between March 2023 and September 2025. The primary outcome was the proportion of patients who fulfilled guideline-based indications and were prescribed the appropriate starting dose of finerenone according to KDIGO recommendations.
resultsA total of 57 patients were included (mean age 70.3 ± 12.9 years). Only 24 (42.1%) fulfilled all KDIGO-based criteria for finerenone initiation and were prescribed the appropriate starting dose. The criterion least frequently fulfilled was the use of a maximally tolerated renin–angiotensin system inhibitor (RASi), achieved in only 32 patients (56.1%). In the subgroup analysis, the annual rate of estimated glomerular filtration rate (eGFR; mL/min/1.73 m²) decline was comparable between the guideline-adherent and non-adherent groups (-6.69 ± 15.32 vs. -5.54 ± 8.41; p = 0.762), and the proportion of patients with albuminuria/proteinuria improvement was also similar (20.8% vs. 42.4%; p = 0.088).
conclusionsA significant proportion of finerenone prescriptions did not adhere to guideline recommendations. These findings highlight the need to strengthen adherence to guideline-based prescribing and monitoring. While our results suggest that finerenone maintains renal efficacy and safety in clinical practice despite suboptimal guideline adherence, further larger clinical studies are warranted to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.